ExcellGene to Manufacture SARS-CoV-2 Trimeric Omicron Spike Protein, Optimized for Subunit Vaccine, Diagnostic and Drug Development
CHO-based cGMP Process Allows for Gram Quantities of Omicron and Delta Spike Proteins
Press release

Dr. Maria J. Wurm CEO, ExcellGene

Dr. Florian M. Wurm CSO, ExcellGene
About ExcellGene SARS-CoV-2 trimeric spike protein products:
- All available variants, summary page
- Omicron Trimeric Spike Protein (in production)
- Delta Trimeric Spike Protein (mg/gram quantities)
- Beta Trimeric Spike Protein (mg/gram quantities)
- Alpha Trimeric Spike Protein (mg/gram quantities)
- Wuhan Trimeric Spike Protein (mg/gram quantities)
Publications on ExcellGene SARS-CoV-2 trimeric spike proteins:
- Pino et al. Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes 2020, 8, 1539. https://doi.org/10.3390/pr8121539
- Joel D. Allen et al., Site-specific steric control of SARS-CoV-2 spike glycosylation. Biochemistry 2021, 60, 27, 2153–2169 https://doi.org/10.1021/acs.biochem.1c00279
- Counoupas et al., Neutralizing Antibodies Against the SARS-CoC-2 Delta Variant Induced by Alhydroxyquim-ll-Adjuvanted Trimeric Spike Antigens. bioRxiv 2021.08.18.456891; https://doi.org/10.1101/2021.08.18.456891
- More at: ExcellGene SARS-CoV-2 Trimeric Spike Proteins
About ExcellGene SA
ExcellGene is a contract development and manufacturing organization (CDMO) dedicated to helping researchers and industry partners who work on vaccines, diagnostics and drug development, by making available high-quality recombinant proteins and high-yielding Chinese Hamster Ovary (CHO) cell-based manufacturing services. The Company, headquartered in Monthey, Switzerland, and its team of 55 located in 16 different countries, is celebrating 20 years of high-quality services in the development and manufacture of therapeutic and vaccine candidate biologics, from DNA to process.
Established in 2001 by Drs. Florian M. Wurm and Maria J. Wurm, as a spin-off from the Swiss Federal Institute of Technology (Lausanne, Switzerland), ExcellGene continues its core focus on innovation and exceptional attention to detail with challenging projects, such as rapid SARS-CoV-2 spike protein production. The Company has served hundreds of clients and pioneered many innovations in the use of recombinant animal cells in bioreactors, and has shared insights and know-how to advance the industry as a whole through well-known publications. ‘Expect Great Science’ is the staple principle underlying all aspects of ExcellGene’s product and customer services. See here for more information.
Point of contact

Sebastian Rheindorf Chief Strategy Officer